Literature DB >> 19758354

Case series of multiple recurrent reactive keratoacanthomas developing at surgical margins.

Jason C Hadley1, Payam Tristani-Firouzi, Scott F Florell, Glen M Bowen, Michael L Hadley.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19758354     DOI: 10.1111/j.1524-4725.2009.01327.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


× No keyword cloud information.
  6 in total

1.  Lower lip recurrent keratoacanthoma: A case report.

Authors:  Xian-Guang Liu; Xing-Guang Liu; Cai-Jiao Wang; Han-Xi Wang; Xu-Xia Wang
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534

2.  Eruptive keratoacanthomatous atypical squamous proliferations (KASPs) arising in skin graft sites.

Authors:  Melanie A Clark; Joan Guitart; Pedram Gerami; Benjamin R Marks; Sapna Amin; Simon S Yoo
Journal:  JAAD Case Rep       Date:  2015-07-29

3.  Multiple reactive keratoacanthomas treated with zinc oxide wraps and intralesional corticosteroids.

Authors:  Lindsey West; Katherine Ayoade; Travis Vandergriff; Rajiv I Nijhawan
Journal:  JAAD Case Rep       Date:  2018-08-15

4.  Triple therapy with intralesional 5-fluorouracil, chemowraps, and acitretin: A well-tolerated option for treatment of widespread cutaneous squamous cell carcinomas on the legs.

Authors:  Iviensan F Manalo; Michael C Lowe; Kelly C Nelson; Suephy C Chen
Journal:  JAAD Case Rep       Date:  2019-11-20

Review 5.  Keratoacanthoma, committed stem cells and neoplastic aberrant infundibulogenesis integral to formulating a conceptual model for an infundibulocystic pathway to squamous cell carcinoma.

Authors:  Steven Kossard
Journal:  J Cutan Pathol       Date:  2020-10-16       Impact factor: 1.587

6.  Keratoacanthoma Arising Over Margin of Porokeratosis of Mibelli: A New Association?

Authors:  Deblina Bhunia; Shouvik Ghosh; Olympia Rudra; Surajit Kumar Biswas; Megha Agarwal; Arghyaprasun Ghosh
Journal:  Indian J Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.494

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.